Moratorium on Human Genome Editing: Time to Get It Right
By Landon J. Getz and Graham Dellaire,
The Hastings Center
| 03. 29. 2019
On March 13, Nature published a call for a global moratorium on heritable human genome editing signed by several prominent CRISPR researchers and bioethicists, including Eric Lander, Françoise Baylis, and Emmanuelle Charpentier. They proposed a temporary moratorium on germline genome editing to create gene-edited children. This moratorium is not designed to stop in vitro research in the laboratory or research on somatic (nonreproductive) cells, but it would cover the implantation of gene-edited embryos or the creation of children using gene-edited sperm or eggs. The authors specifically cite safety, scientific, technical, medical, and ethical/moral/societal reasons for calling the moratorium. Importantly, it is supported by the National Institutes of Health in the United States and the European Society for Human Reproduction and Embryology (ESHRE).
Although some criticism, notably from CRISPR pioneer Jennifer Doudna (who did not sign the moratorium statement), has focused on the possibility of a moratorium “of indefinite length,” this argument is somewhat of a straw man as the proposed moratorium is temporary. Doudna has also criticized a moratorium as being something that will suppress open discussion and...
Related Articles
Not the species, certainly, but the Institute of that name, which was founded by transhumanist philosopher Nick Bostrom in 2005 as a research group at Oxford University. According to a recently posted Final Report, its goal was “to pursue the big questions in a transdisciplinary way” by pulling together “researchers from disciplines such as philosophy, computer science, mathematics, and economics.” This evolved before long into the study and promotion of “effective altruism” and “longtermism” as...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...